Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336735 | 0.89 | MAPT (0.42) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL19615264 | 0.83 | ALDH1A1 (0.40) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL25303289 | 0.82 | RAB9A (0.49) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL22900489 | 0.82 | KMT2A (0.46) | MAPTSMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL19618984 | 0.82 | POLB (0.40) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL24552650 | 0.82 | ALDH1A1 (0.41) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL19615850 | 0.82 | ALDH1A1 (0.39) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL22436658 | 0.81 | MEN1 (0.45) | MAPTSMN1; SMN2ALDH1A1RAB9ANPC1 | |
| SCHEMBL19615438 | 0.81 | SLC5A1 (0.42) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A | |
| SCHEMBL24553235 | 0.80 | KDM4E (0.47) | MAPTSMN1; SMN2ALDH1A1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | MyricX Pharma Limited (GB) | 2026-04-14 | — | — | US | disclosed |
| US-20260049075-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MYRICX PHARMA LTD (GB) | 2026-02-19 | — | — | US | disclosed |
| EP-4583979-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| CN-119968369-A | Cytotoxic imidazo [1,2-a ] pyridine compounds and their use in therapy | 迈里克斯制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12152041-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4460498-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2024052685-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052685-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2024-03-14 | — | — | WO | disclosed |
| EP-3243814-A1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | AbbVie Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2134684-B1 | 7-SUBSTITUTED INDOLE AS MCL-1 INHIBITORS | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9359296-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9035047-B2 | 7-substituted indole Mcl-1 inhibitors | ABBVIE INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBVIE INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8445679-B2 | 7-substituted indole MCL-1 inhibitors | ABBVIE INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2134684-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008131000-A2 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152041-B2 | Macrocyclic fluorine substituted indole derivatives | FOXM1, CCNT2, CCND2 | MAPT 3107/4885SMN1; SMN2 3638/4885ALDH1A1 1201/4885 |
| US-20260049075-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | XPA, FLT3, TPMT | MAPT 4311/4885SMN1; SMN2 145/4885ALDH1A1 3485/4885 |
| US-20260048136-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | SLC7A1, FLT3, ABL1 | MAPT 3885/4885SMN1; SMN2 398/4885ALDH1A1 2177/4885 |
| US-20140051683-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MAPT 3221/4885SMN1; SMN2 1744/4885ALDH1A1 2525/4885 |
| US-12599676-B2 | Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy | ABL1, FLT3, MTX2 | MAPT 4059/4885SMN1; SMN2 192/4885ALDH1A1 2148/4885 |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | MAP3K20, MAP3K8, PRKACA | MAPT 2010/4885SMN1; SMN2 3339/4885ALDH1A1 4849/4885 |
| US-20150284328-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MAPT 3221/4885SMN1; SMN2 1744/4885ALDH1A1 2525/4885 |
| US-20090054402-A1 | 7-SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, API5 | MAPT 3221/4885SMN1; SMN2 1744/4885ALDH1A1 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.